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 Introduction: As the susceptibility profiles of Pseudomonas aeruginosa grow increasingly 
resistant to existing antimicrobial therapies, there is a critical need for effective combination 
therapy. Polymyxin B based combinations may improve clinical outcomes by utilizing its rapid 
killing potential in conjunction with the sustained action of meropenem. The objective of the 
study is to evaluate the pharmacodynamic activity of polymyxin B in combination with 
meropenem against Pseudomonas aeruginosa clinical isolates. Antibiotics used in combination 
should have better pharmacodynamic killing activity against P. aeruginosa clinical isolates and 
should result in suppressed regrowth patterns as compared to monotherapy.  
Methods: In-vitro static time-kill experiments were performed using P. aeruginosa clinical 
isolates with differing susceptibilities, polymyxin B resistant (PBr) strain PSA215 and polymyxin B 
sensitive (PBs) strain PSA218 to evaluate the killing activity of polymyxin based combinations with 
meropenem.  
Results: Against PBr isolate, PSA215, combination therapy produced moderate improvements in 
killing activity as well as slowed regrowth but was unable to achieve sustained killing over 24 h. 
Against PBs isolate, PSA218, combination therapy showed moderate ability of sustained killing (3 
of 8 combinations resulted in bactericidal activity) but not a significant improvement compared 
to meropenem monotherapy.  
Conclusion: While the results of the experiment showed the combination ineffective for the 
bactericidal endpoint, potential improved killing and suppressed regrowth patterns with the 
combination of polymyxin B and meropenem was seen in first 8 h. Further testing with isolates 
of varying susceptibilities are necessary to understand the extent of effect by this combination 




Pseudomonas aeruginosa is an opportunistic pathogen capable of infecting a range of 
tissues and ranking as one of the top six infectious disease threats.1 This major pathogen 
contributes to mortality related to many respiratory diseases including cystic fibrosis (CF) and 
hospital acquired pneumonia.1 Pseudomonas aeruginosa, as a Gram-negative pathogen that 
commonly colonizes airways and forms biofilms that can proliferate and traverse the mucosa, 
poses a great concern for CF patients, pneumonia, as well as bacteremia and infection of distant 
organs.2 Resistance rates to major monotherapies are gradually increasing such as imipenem 
resistance in nearly 40% of cases, fluoroquinolones in 33% of cases, and beta lactams in 26% of 
cases.3 Unfortunately the pharmaceutical pipeline of antimicrobial therapies active against multi-
drug resistant Gram-negative bacteria has been limited.4 Over the last three decades, there has 
been a resurgence of infectious disease as bacterial pathogens adapt and overcome the pressure 
of antimicrobial therapies on their environment.5 Pseudomonas aeruginosa presents a significant 
challenge as it can develop resistance to multiple classes of antibacterial agents even within the 
time of a course of treatment.5 P. aeruginosa can develop resistance through genes imported by 
utilizing horizontal gene transfer. Examples include the production of beta lactamases and 
carbapenem-hydrolyzing enzymes.5 Some of these resistance mechanisms such as 
carbapenemases come from genes imported from Klebsiella pneumoniae and Acinetobacter 
baumanii while others are encoded within the P. aeruginosa through chromosomal mutations 
such as the quinolone resistance mechanisms of gyrase and topoisomerase mutations.5  
Levels of resistance are categorized as Multi-Drug Resistant (MDR), Extensively Drug 
Resistant (XDR), and Pandrug Resistant (PDR).6 Table 1 shows the different antimicrobial 
categories for Pseudomonas aeruginosa treatment. The categorizations of drug resistance are 
sorted by the number of antimicrobial classes that the strain is resistant to, with MDR being 
resistance to more than 1 agent from 3 classes, XDR as resistance to at least 1 agent from 6 of 
the 8 classes, and PDR being resistance to all antimicrobials listed.  
Antimicrobial Class Antimicrobial Agent 
Aminoglycosides Gentamycin, Tobramycin, Amikacin, Netilmicin 
Carbapenems Imipenem, Meropenem, Doripenem 
Cephalosporins Ceftazidime, Cefepime 
Fluoroquinolones Ciprofloxacin, Levofloxacin 
Penicillin + Beta-lactamase inhibitors Piperacillin-tazobactam, Ticarcillin-clavulanic acid 
Monobactams Aztreonam 
Phosphonic Acids Fosfomycin 
Polymyxins Colistin, Polymyxin B 
While there is a large spectrum of bacteria that commonly cause hospital acquired 
pneumonia, our lab’s focus is on ESKAPE pathogens like Klebsiella pneumoniae, Acinetobacter 
baumanii, and Pseudomonas aeruginosa. Pneumonia due to Pseudomonas aeruginosa is 
commonly associated with green sputum, abscess formation, and is commonly seen in patients 
with cystic fibrosis or severely compromised respiratory defenses.5,7 It is an opportunistic 
pathogen that commonly colonizes airways and forms biofilms that traverse the mucosa and 
infect distant organs.2 As stated previously, P. aeruginosa employs many resistance mechanisms 
such as the production of beta lactamases and carbapenemases. Thus, combination therapy may 
prove an effective strategy by utilizing different mechanisms of action to circumvent resistance 
mechanisms in bacterial colonies and enact stronger bactericidal activity for suppression of 
further resistance. The severe lack of antimicrobial advancement for MDR Gram-negative 
Table 1. Examples of antimicrobial agents to classify susceptibility to fit in MDR, XDR, and PDR 
definitions. 
 
bacteria has caused a resurgence in the use of older antibiotics including polymyxin and 
fosfomycin.4  
Polymyxin is a class of antibiotics that work by binding to lipopolysaccharide in the outer 
membrane of Gram-negative bacteria, damaging the hydrophobic tail and causing a detergent-
like action. This class of antibiotics displays extensive killing profiles in monotherapy, but 
unfortunately presents rapid regrowth due to resistant subpopulations proliferating after 
suboptimal treatment.8 Unfortunately, reaching therapeutic concentrations of polymyxin class 
antimicrobial therapies presents an issue due to nephrotoxicity occurring in significant numbers 
of patients.9 A strategy to work around this is a front loaded dosing regimen that utilizes the 
polymyxin’s ability for extensive bactericidal activity while reducing overall cumulative drug 
exposure.10 Using polymyxins as the initial agent may prove effective against the MDR P. 
aeruginosa strains while relying on the other antibiotics for suppression of regrowth.  
Carbapenems are consistently effective agents for treatment of serious P. aeruginosa 
infections of susceptible strains.11 Carbapenems are members of the beta lactam class of 
antibiotics and work by entering the cell through porins and acylate penicillin binding proteins 
(PBP) that prevent the formation of the peptidoglycan layer.12 Carbapenems provide broad 
spectrum coverage and are usually reserved for severe infections.12 Unfortunately, resistance 
mechanisms have grown with the rise of MDR bacteria. Carbapenem resistance usually occurs 
through loss of OprD, a porin protein present on the outer membrane of the Gram-negative 
bacteria that regulates entry of carbapenems. Overexpression of MexAB-OprM, an intrinsic efflux 
system and production of AmpC, for carbapenem-hydrolyzing beta lactamases, are other 
resistance mechanisms.  
Pharmacokinetic and pharmacodynamic studies of combination therapies in resistant 
Pseudomonas aeruginosa strains are limited. Further studies should be promoted to better 
characterize interaction, onset of action, and development of resistance. The aim of this project 
is to combine the extensive killing profiles of polymyxin with the sustained activity of meropenem 
to identify characteristics of combination effects and optimal doses for both PBr and PBs 





isolate polymyxin B meropenem 
PSA203 0.5 S 0.5 S 
PSA200 1 S 0.5 S 
PSA225 1 S 0.5 S 
PSA218 1 S <0.5 S 
PSA219 2 S 0.5 S 
PSA202 8 R 16 R 
PSA215 16 R 2 S 
PSA205 64 R 4 I 
 
Minimum Inhibitory Concentration Testing. 8 Pseudomonas aeruginosa strains were tested with 
MICs ranging from 0.5 to 64 mg/L for polymyxin B and 0.5 to 16 mg/L for meropenem (Table 2). 
The two strains selected were PSA215 for its polymyxin B resistance compared to PSA218 for its 
polymyxin B susceptibility, with both susceptible to meropenem. The polymyxin sensitivities of 
PSA215 and PSA218 were 16 and 1 mg/L respectively. Their meropenem sensitivities were 2 and 
<0.5 mg/L respectively.  
Table 2. MIC in mg/L of 
Pseudomonas aeruginosa 
isolates utilizing broth 
microdilution assay. 
Susceptiblity based on EUCAST 




Pharmacodynamic activity. Monotherapy. Time-kill curves for polymyxin B and meropenem 
monotherapies against P. aeruginosa strains PSA215 and PSA218 shown in Figure 1. The 
polymyxin B resistant (PBr) strain PSA215 resulted in regrowth after initial killing for polymyxin B 
concentrations of 0.5, 1, 2 and  4 mg/L but polymyxin concentrations of 8 and 16 mg/L resulted 

















Figure 1. Time-kill curves of polymyxin B (PMB) monotherapy at 0.5, 1, 2, 4, 8, 16 mg/L and 
meropenem (MEM) monotherapy at 10, 20, 40, 80, 160 mg/L against an inoculum of ~106 CFU/mL 
of the P. aeruginosa strains PSA215 (polymyxin B MIC, 16 mg/L; meropenem, 2 mg/L) and PSA218 
(polymyxin B MIC, 1 mg/L; meropenem, <0.5 mg/L) 
 
concentration dependent killing. Increasing concentrations of both polymyxin b and meropenem 
resulted in increased killing against PSA218 in a dose proportional manner. The extent of activity 
≥3-log10 CFU/mL reduction in the inoculum was greater for meropenem monotherapy in PSA218 




























Figure 2. Time-kill curves of polymyxin B (PMB) at 0.5, 1, 2, 4 mg/L in combination with 
meropenem (MEM) at 10 and 40 mg/L against an inoculum of ~106 CFU/mL of the P. 
aeruginosa strains PSA215 (polymyxin B MIC, 16 mg/L; meropenem, 2 mg/L) and PSA218 
(polymyxin B MIC, 1 mg/L; meropenem, <0.5 mg/L) 
 
Combination therapy. Time-kill curves for polymyxin B (0.5, 1, 2, 4 mg/L) and meropenem (10 
and 40 mg/L) combination therapies against P. aeruginosa strains PSA215 and PSA218 are shown 
in Figure 2. Polymyxin B in combination with meropenem against PSA215 resulted in increased 
killing activity and delayed growth compared to either monotherapy. Combination therapy 
against PSA218 resulted in increased killing and similar rates of regrowth compared to 
meropenem monotherapy. Certain concentrations, namely 1 mg/L PMB; 10 mg/L MEM PSA215, 
4 mg/L PMB; 10 mg/L MEM PSA215, 2 mg/L PMB; 40 mg/L MEM PSA215 and 4 mg/L PMB; 40 
mg/L MEM PSA215 showed lack of initial CFU/mL data. The extent of killing is shown more 
accurately in Table 3, where it is seen that only 3 combinations of PSA218 were able to meet the 
criteria of bactericidal activity defined as ≥3-log10 CFU/mL reduction in the inoculum as 




MEM at 10 mg/liter plus PMB at: MEM at 40 mg/liter plus PMB at: 
Strain Time (h) Control 0.5 mg/L 1 mg/L 2 mg/L 4 mg/L 0.5 mg/L 1 mg/L 2 mg/L 4 mg/L
PA215 2 0.347 -3.125 1.301 0.000 0.000 -3.903 -1.097 0.000 0.000
4 1.824 -4.903 0.000 0.000 0.000 -4.079 -0.967 0.000 0.000
8 2.268 -3.602 0.000 1.301 0.000 -3.301 -0.018 0.000 0.000
24 2.847 6.556 4.453 4.895 2.301 4.954 6.602 0.000 0.000
PA218 2 -0.301 -3.0872 -3.5441 -5.3424 -3.6021 -2.2041 -6.1703 -3.5819 -2.2451
4 1.875 -3.4393 -5.4472 -5.3424 -4.9031 -3.6301 -6.1703 -5.9243 -3.9031
8 2.398 -0.2632 -5.4472 -5.3424 -4.9031 -4.5051 -6.1703 -5.9243 -5.5051
24 3.455 1.1139 -3.1919 -2.0414 -3.1249 -0.8667 -1.8692 -1.7782 -4.2041
Change in log10 CFU/mL
Table 3. The change in log10 CFU per milliliter at 2, 4, 8, and 24 h during time-kill experiments 
with combination therapy of polymyxin B and meropenem against an inoculum of ~106 
CFU/mL of P. aeruginosa isolates PSA215 and PSA218.  
 
Decision to not advance experimental data collection. Due to the time commitment required 
to collect data for in vitro time kill assays, the decision was made that further data collection for 





The threat of these MDR Gram-negative infections is increasing rapidly and suboptimal 
treatment is a culprit to exacerbation of the resistance mechanisms. Current clinical regimens 
are struggling to optimally treat Gram-negative infections, creating the opportunity for resistant 
populations to flourish and regrow. Thus, the pharmacodynamic and pharmacokinetic data 
derived from static time-kill assays are the pivotal first step to reformulating regimens for novel 
dosing strategies that achieve therapeutic efficacy for infectious resolution as well as resistance 
suppression.  
This study compared the efficacy of the polymyxin B meropenem two-drug combinations 
against a PBr strain and a PBs strain of P. aeruginosa. With the primary endpoint of bactericidal 
killing defined as ≥3-log10 CFU/mL reduction in the inoculum, neither the monotherapy nor 
combination therapy was able to achieve treatment success for the PBr PSA215. Despite this, the 
results show the improved bactericidal activity early on in combination but were unable to 
improve regrowth rates by 24 h compared to monotherapy. Overall improvement of the area 
under the time-kill curve was the only visible benefit and requires additional data points for 
conclusive analysis of polymyxin B meropenem combination in PBr strains. Also, 4 of the 8 tested 
combinations in PSA215 showed experimentally erroneous data, namely: 1 mg/L PMB; 10 mg/L 
MEM PSA215, 4 mg/L PMB; 10 mg/L MEM PSA215, 2 mg/L PMB; 40 mg/L MEM PSA215 and 4 
mg/L PMB; 40 mg/L MEM PSA215.  
Two drug combinations on PBs PSA218 resulted in improved killing compared to 
polymyxin B monotherapy, but not compared to meropenem monotherapy. The extent of killing 
overall was improved during the first 8 hours utilizing combination therapy, but the extent of 
regrowth at the 24 h time point was not significantly improved compared to meropenem 
monotherapy. With all 4 concentrations of meropenem monotherapy reaching bactericidal 
primary endpoint and only 3 of 8 combinations reaching bactericidal activity, the results cannot 
conclude any combination effects in PBs and meropenem susceptible strains.  
Overall this study shows that the combination of polymyxin B and meropenem has 
potential in altering the bactericidal activity within the first 8 hours but does not improve the rate 
of regrowth overall. This result is a limitation of the 24 h static time-kill as it does not accurately 
assess dosing regimens such as extended infusion dosing intervals to translate pharmacokinetic 
activity in the human body. While time-kill assay is a good indicator of pharmacodynamic activity, 
future assessments of the polymyxin B and meropenem combinations should utilize one-
compartment and Hollow Fiber models to mimic clearance and various dosing regimens for 
pharmacokinetic activity. A major disadvantage of the time-kill experiments is the need for 
repeated sampling, which is quite labor-intensive and prone to experimental error.15 In vitro 
analysis cannot assume straightforward in vivo efficacy as it does not examine toxicity and cannot 
predict in vivo development of resistance, especially with host immune factors in play.16 A major 
limitation of this study is that it assesses only two clinical isolates of PBr and PBs susceptibility. 
Analysis of multiple PBr and PBs isolates could provide more useful trend information that is not 
shown with time-kill assays of individual strains that cannot accurately represent the entirety of 
MDR P. aeruginosa.   
Tangden et al. evaluated the effects of colistin and meropenem against P. aeruginosa and 
concluded that colistin and meropenem showed combination effects and improved early 
dynamics. They found that combination resulted in enhanced 1 h, 24 h, and 8 h bacterial 
reductions against 2, 3, and 5 of 8 strains respectively.15 These findings are in line with the results 
of the current study which identifies improved pharmacodynamic profiles within the 8 h window.  
Within the current literature, bactericidal activity of Pseudomonas aeruginosa increases 
from 10 to 49% when combining polymyxins with carbapenems.16 Rates of colistin resistance 
were also suppressed and delayed by combination with doripenem.17 Unfortunately, not all 
literature agrees with these findings. While synergy with polymyxin carbapenem combinations 
has been found often in Klebsiella pneumoniae and Acinetobacter baumanii, studies such as 
Timurkaynak et al. show indifferent or only additive benefits to the combination.18,19 It has also 
been identified that meropenem is the least synergistic carbapenem with polymyxins against 
Pseudomonas aeruginosa.16  
Combination therapy utilizing polymyxin-carbapenem regimens is becoming increasingly 
studied and showing high rates of synergy with low antagonism and less resistance development. 
Assessment of novel regimens such as front-loading antibiotics could utilize the 
pharmacodynamic synergy of the combination while minimizing the exposure to polymyxin and 
meropenem to lessens exposure of nephrotoxic and hepatotoxic risks.10 
In conclusion, the in-vitro static time-kill assays of PSA215 and PSA218 did not show 
marked improvement in 24 h sustained pharmacodynamic activity. Despite this, changes within 
8 h pharmacodynamic activity showed the improved extent of killing that indicates combination 
effects that may be viable for novel dosing regimens. Extended studies with models that allow 
for variable dosing frequencies and drug clearance can further the understanding of these drug 
combination effects and optimize regimens for practical clinical use that minimizes the adverse 
effects of the antibiotics while improving bactericidal activity and inhibiting regrowth.  
To expand on the topics covered through this study, a review of literature was conducted 
on Applications of Machine Learning for Clinical Decision Making in Infectious Disease to be 
presented at ASHP Midyear as a poster presentation. Due to the time constraints of the pharmacy 
student, this alternate project was pursued for continued scholarship within the lab group while 
data continuing the analysis of P. aeruginosa time kill assays was put on hiatus for potential 
continuation by other lab group members.  
 
  
Materials and Methods:  
Over 30 Pseudomonas aeruginosa isolates were collected from adult cystic fibrosis 
patients in Brazil. These isolates were analyzed in a separate part of the lab for hypermutators 
and MICs were tested using a standard broth microdilution antimicrobial susceptibility test. The 
strains focused on these experiments are non-hypermutators to provide comparison data to the 
hypermutators. A range of MIC susceptibility allows for comparison in effectiveness of drug 
combinations.  
 MIC Testing: Minimum inhibitory concentration (MIC) for these strains were determined 
to understand the susceptibility of these strains to different monotherapies. MICs were 
determined in triplicate using broth microdilution according to Clinical and Laboratory Standards 
Institute (CLSI) guidelines.14 
The selected Pseudomonas aeruginosa clinical isolates, PSA218 and PSA215, were 
subjected to polymyxin B monotherapy, meropenem monotherapy, and dual combination 
therapy. In-vitro static time-kill experiments were performed over 24 h to evaluate the rate and 
extend of killing:  
Time-Kill Preparation: Bacteria was applied to a Mueller-Hinton broth (Becton, Dickinson 
and Company, Sparks, MD) to a targeted initial concentration of 107 CFU/mL. Varying 
concentrations of polymyxin B (0.5, 1, 2, 4, 8, 16 mg/L) and meropenem (10, 20, 40, 80, 160 mg/L) 
were prepared using sterile water and saline and was applied to each tube so that, along with a 
control, a different combination of antibiotic dose was tested in each tube. The concentrations 
were chosen based on free concentrations in the blood corresponding to currently existing 
therapeutic doses.  
Time-Kill Experiment: Samples were collected at the 0, 2, 4, 6, 8, and 24-hour time points 
to determine rates of killing and regrowth. The bacteria previously prepared are diluted into 
warm Mueller-Hinton broth for a 1:10 dilution creating a 106 CFU/mL bacterial inoculum. At each 
time point, individual samples were assessed for bacterial growth visually and diluted with 
normal saline to achieve plate growth in a reasonable range for visual colony assessment.  
Microbial Quantification: 50 µL samples were plated onto Mueller-Hinton II agar (MHA; 
Becton, Dickinson and Company, Sparks, MD) using a Whitley Automated Spiral Plater II (Don 
Whitely Scientific, West Yorkshire, UK) and incubated at 37°C for ~24 hours for assessment of  
colony formation. Colony assessment, measured in log10 CFU/mL, was quantified using ProtoCOL 
HR automated bacterial colony counter (Synbiosis, Frederick, MD) 
Pharmacodynamics: Utilizing the data from the colony counter, data was graphed to 
assess CFU/mL over time. Primary endpoint of bactericidal activity is defined as ≥3-log10 CFU/mL 
reduction in the inoculum by 24h. With the results of minimal regrowth maintaining <2-log10 
CFU/mL overall, therapies can be determined as successful and that data can be utilized to 
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